Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
1997-07-21
2001-03-06
Witz, Jean C. (Department: 1651)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C623S011110, C623S017120, C623S001210
Reexamination Certificate
active
06197296
ABSTRACT:
INTRODUCTION
This invention is concerned with the creation of tissue equivalents and methods for their preparation. Although reference will be made hereinafter to the preparation of vascular grafts, it should be understood that the present invention has applications to various other tissue equivalents, for instance heart valves. The invention has application to a suitable implantable or reconstructive material with an active cellular lining, for example endothelial, whether autologous or not.
BACKGROUND TO THE INVENTION
There are a number of clinical situations in which implants are required. A vascular graft may be desirable in order to replace a section of vessel damage during trauma, or to bypass vessels exhibiting occlusive diseases, for instance, for coronary artery bypass. The two major alternatives available for vascular grafting are the use of an autologous vessel from elsewhere in the body, or the use of biological or synthetic prostheses. Both alternatives have drawbacks. The former may be surgically time consuming and availability limited. Prosthetic materials, while surgically convenient, have a number of performance disadvantages.
Coronary artery bypass grafting remains the most effective longer term treatment for coronary artery disease. Since the introduction of the bypass technique, many different types of vascular grafts have been evaluated. The most obvious source of a vascular conduit is autologous vein or artery removed or transposed from elsewhere in the body. Saphenous vein and internal mammary artery have been used. Saphenous vein conduits suffer from early thrombotic occlusion and also from late failures so that more than 50% have occluded by 10 years. A major drawback with the use of autologous material is that, when occlusion does occur, there is often insufficient autologous conduit left for re-operations. This is particularly relevant when multiple bypass operations are required. Alternatively, saphenous vein may be unavailable, for instance, due to varicosities.
Artificial prostheses constructed from such diverse materials as woven Dacron™, Gore-Tex™ and expanded microporous polytetrafluoroethylene all suffer to a greater or lesser extent from thrombus formation. Attention has therefore turned towards biological grafts of non-autologous origin.
Allograft veins and arteries from post mortem donors have been used with variable success. However, reliance on this source is unlikely to fulfil demand. To overcome this availability problem, the use of human umbilical veins and arteries has been considered. Unfortunately, these have exhibited poor mechanical performance and rapid occlusion.
Following the successful use of glutaraldehyde preserved animal valves in valve replacement surgery, many groups turned to xenografts as a possible source of vascular replacements. Xenografts need to be chemically modified in order to decrease immunogenicity and increase resistance to resorption. Glutaraldehyde has been the commonest crosslinking agent used. However, its side effects include cytotoxicity which could inhibit endothelial re-colonisation and increased stiffening leading to kinking and a lack of stretch and elasticity. When a less severe crosslinking regimen was used, using aldehyde vapour, only a temporary resistance to degradation was seen. This is likely to lead to an increased risk of aneurysm formation.
U.S. Pat. No. 4,546,500 discloses the preparation of a vessel equivalent from a series of layers of gel contracted from aqueous mixtures of collagen fibrils, a nutrient medium and smooth muscle cells or fibroblast cells. In addition, it has been suggested to include a Dacron™ mesh between two layers of the multi-layer structure. The addition of a second layer of collagen resulted in a multi-laminated structure in which the mechanical strength was provided by the Dacron™ alone. These blood vessel equivalents, constructed from several layers of collagen and Dacron™, have been shown to suffer from delamination problems. The use of fibrin as a biological glue to adhere the collagen layers together has since been employed. It is an object of this invention to overcome this problem.
In addition, it is an object of this invention to improve the preconditioning of the tissue equivalents to the pressures—e.g. blood pressure—to which it will be subjected within the body.
SUMMARY OF THE INVENTION
According to a first aspect of the present invention, there is provided a method of forming a tissue equivalent comprising impregnating a fibrous substrate with collagen fibrils, applying to the impregnated substrate an aqueous mixture of collagen fibrils, a nutrient medium and a cellular contractile agent, and incubating the system to allow a gel to form from the aqueous mixture and to contract and express aqueous medium therefrom. By pre-impregnating the fibrous substrate with solubilised collagen, followed by casting a single collagen gel, the problems of delamination are avoided. Using the process of the present invention, collagen has been shown to infiltrate and interweave within the synthetic structure and to be reorganised within it an a coherent whole. The preferred fibrous substrate is Dacron™ fabric.
The fibrous substrate may be impregnated by soaking in an acidic aqueous collagen solution. This is preferable as it holds the collagen in solution during the impregnation. Subsequently, an alkaline aqueous mixture of collagen fibrils, a nutrient medium and a cellular contractile agent may be applied to neutralise the acidic impregnation of the substrate and initiate collagen fibrillogenesis. The cellular contractile agent will usually comprise smooth muscle cells.
Thrombogenicity may be prevented by covering the tissue equivalent with a monolayer of functional endothelial cells (EC). The attachment and activity of these cells may be enhanced by their interaction with the underlying SMC populated collagen matrix, resulting in the formation of basement membrane.
According to a second aspect of the present invention, there is provided a method of forming a tissue equivalent comprising forming a contracted gel from an aqueous mixture of collagen fibrils, a nutrient medium and a cellular contractile agent, lining the tissue equivalent with endothelial cells, applying an aqueous fluid under pressure to the face or faces of the tissue equivalent lined with endothelial cells and preconditioning the tissue equivalent by incubating the system whilst increasing the pressure applied to the said face or faces of the tissue equivalent. The endothelial cells applied to a tissue equivalent formed in accordance with the first aspect of the invention may be applied in this way. By using hydrostatic and/or hydrodynamic preconditioning, the remodelling of the collagen fibrils can be influenced. In this way, the alignment of the resulting fibres may be of structural importance as they tend to align in such a way as to account for the stresses imposed by the pressurised fluid.
The lining of the tissue equivalent with endothelial cells may involve exposing it to cultured endothelial cells in a cell support medium. Similarly, the pressurised may be an endothelial support medium.
REFERENCES:
patent: 3272204 (1966-09-01), Artandi et al.
patent: 3400719 (1968-09-01), Eckhart
patent: 4546500 (1985-10-01), Bell
patent: 4721096 (1988-01-01), Naughton et al.
patent: 4963489 (1990-10-01), Naughton et al.
patent: 5032508 (1991-07-01), Naughton et al.
patent: 5863531 (1999-01-01), Naughton et al.
patent: 0393788 (1990-10-01), None
patent: 0418035 (1991-03-01), None
patent: 0457430 (1991-11-01), None
patent: 8203764 (1982-11-01), None
Foxall, Thomas L., et al., “Adult Human Endothelial Cell Coverage . . . ”Journal of Surgical Research,41, pp. 158-172 (published, Aug. 1986).
Miwa H., et al., “Development of Hierarchically Structured . . . Graft,”Jpn. Artif. Organs,22(2):468-472 (published, Feb. 22, 1993).
Kanda K., et al., “A Highly Structured Hybrid Artificial Media, . . . ,”Jpn. Artif. Organs,22(2):478-482 (published, Feb. 22, 1993).
K. Kanda et al., “Phenotypic Modulation of Smooth Muscle Cell
Browne Tom
Davies Alban
Haynes Sarah
Kearney John
National Heart Research Fund
Schindler Edwin D.
Witz Jean C.
LandOfFree
Tissue equivalents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue equivalents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue equivalents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2513065